Amr Abdel Moneim Abdel Rahman Saad, Bpharm, MSc, PhD
The Former Associate Minister of Health for Pharmaceutical affairs
The Founder of the common Arab Guidelines for Pharmacovigilance
The Founder of the Egyptian Pharmaceutical Vigilance Center
Clinical Lecturer in several Egyptian Universities

Biography

Dr Amr Saad got his **Ph.D. in Epidemiology** from The University of Manchester in UK in 2009. He participated in more than 240 national and international conferences where he published many scientific researches all of which are abstracted in the PubMed, and more than 60 posters and countless numbers of speeches in national and international events. He is a well-known worldwide figure in the field of Pharmacovigilance and drug safety monitoring. He was **the Associate of the Egyptian Minister of Health and founder of the Egyptian Pharmaceutical vigilance Center (EPVC) and Founder of the Egyptian Pharmaceutical Vigilance Center**. He is also the Head & Member of several regulatory committees, e.g.: Supreme Egyptian consultancy committee for Egyptian MOH, Pharmacovigilance, Pharmaco-economics, research ethics, CTD preparation, and clinical Pharmacy fellowship committees. He had the good fortune also to be a member of the three committees responsible for establishment and updating Egyptian Lists for Essential Drugs (EDL), Life Saving Drugs (LSD) and Over the Counter medicines (OTC), as well as, working group against SSFFC Medicines, and the representative of the Pharmaceutical Sector in the Crisis Management Committee in the Egyptian ministry of health.

- **While being** the Associate Minister of Health for the pharmaceutical sector. His delegated responsibilities include the reform of the whole sector with increasing capacity and establishing the Egyptian Drug Authority.
- He was also member of **the higher consultancy committee for the Egyptian Minister of Health.**
- **Before that**, he worked very hard to unify guidelines and performance across the Arab world in the field of Pharmacovigilance. This resulted in the issue of a common decree from the Arab ministers of health [(number 7) in their 37th regular meeting in March 2012] to unify PV guidelines in all Arab World. Thus, "'The Higher Technical Committee for Medicines" was established with representatives from all Arab countries, to create these common Arab guidelines in

pharmacovigilance, and in bioequivalence. This committee elected Dr Amr Saad to lead the committee across all its rounds. The committee finished the final drafts of the two common guidelines which were submitted to the 41st regular ministers meeting, and which has been approved by them.

- **He is also a** Current member of the national research ethics committee.
- A Current member of the national clinical pharmacy fellowship scientific board.
- A Current subject matter expert and main consultant for the establishment of the Egyptian Drug Authority (EDA).
- A Current subject matter expert for the Arab League for the running of the pharmacovigilance workshop across the Arab countries

- **He is also a Lecturer of clinical pharmacy** at Future University of Egypt (FUE), Misr International University (MIU), Cairo University & Ain Shams University, Ahram Canadian University (ACU), Suez Canal University, German University in Cairo (GUC) & British University of Egypt (BUE) where he is involved in the construction of the course content, scheduling the content, lecturing, and student evaluations (written and oral).
- **He is also an external evaluator for clinical pharmacy curricula & External oral examiner** at Future University of Egypt (FUE), Misr International University (MIU), Cairo University & Ain Shams University, Ahram Canadian University (ACU), Suez Canal University, German University in Cairo (GUC) & British University of Egypt (BUE).
- **He is also the developer for the Pharm D, Masters & PhD courses** for the Faculty of Pharmacy, Suez Canal University
- **He is also a founding member in the Egyptian Clinical Pharmacy fellowship**. His responsibilities included the constructing the course content, facilitating the infrastructure, scheduling the content, lecturing, and co-ordinating with other international bodies for the recognition of the fellowship (university college cork (UCC) in Ireland).
- **He is also a member of the national research ethics committee (REC)** within the Egyptian ministry of Health.
- **He is also a member in some Scientific and Technical Committees** within the Egyptian Drug authority like: Pharmacovigilance, Non-Referenced Products, Essential Medicines List, Life Saving medicines, Non-Prescription Medicines, Pharmaco-economics, SSFFC.
- **Being the founder of the Egyptian Pharmaceutical vigilance Center (EPVC)**, His responsibilities included the construction of a national center to monitor adverse drug reactions (ADRs) from scratch. This included the recruitment of personnel; training and educating them; setting the work plan; defining guidelines and SOPs; structuring the time plan; establishing the national yellow card system; constructing the website; developing the national database for ADRs; conducting awareness campaign in universities, hospitals and for health care professionals

(HCPs); and registering and reporting to the WHO-Uppsala Monitoring Center (WHO-UMC). These included working in **Five main dimensions to establish the culture of Adverse Drug Reactions (ADRs) reporting in Egypt from scratch**. The **first** dimension was awareness campaigns and training to Health Care professionals (HCPs; Physicians, Pharmacists, Dentists, Physiotherapists, Corners and nurses) on pharmacovigilance through series of waves of workshops, conferences and trainings that included more than 6000 professionals during the years 2011/2012. **The second** dimension was introducing the teaching of this new science in the curricula of faculties of medicines, pharmacies and nurses via co-ordination with the supreme council of higher education. It is now being delivered to undergrads and postgraduates in 12 different universities. I was also involved in the direct teaching of this science in three different universities under the departments of clinical pharmacy. **The third** dimension was securing the legal frame work and obligations within the ministry of health that necessitates the presence of pharmacovigilance infra structures and dedicated departments in all pharma-companies and Marketing Authorization Holders (MAHs) working in Egypt to maintain their license and keep the registration of their products. **The fourth** dimension was enforcing the involvement of Egypt in the global networking of Pharmacovigilance and the International WHO Program for Adverse Drug Reactions Monitoring. Introducing Egypt as one of the active members in the international society was a challenge that has been met successfully. **The fifth** dimension was the establishment, maintaining and running the national regulatory pharmacovigilance committee, and he currently is the head of this committee that meet on a weekly basis to discuss safety issues and propose regulatory actions that ranges from amending the SPCs up to conducting Post Authorization Safety Studies (PASS). Very recently, he is working on establishment of **a nationwide network of satellite centers for Pharmacovigilance** working under the umbrella of the main Center at the regulatory authority. Current chosen governorates that were selected are: Alexandria, Monofya & Cairo.